In a landmark move to strengthen Uganda’s healthcare system and reduce dependency on imported medical supplies, the country has commenced local production of rapid diagnostic test (RDT) kits for HIV, malaria, and sickle cell disease.
This significant development is spearheaded by Microhaem Scientifics (MHS), whose state-of-the-art diagnostic test kit manufacturing plant in Ntinda, Kampala, is set to revolutionize disease detection and management across the nation.
The first phase of production at the MHS facility, which was commissioned in 2023, has already yielded two million RDT kits. These were officially handed over to the National Medical Stores (NMS) for nationwide distribution.
This momentous occasion marks the beginning of a new era in Uganda’s medical landscape, where reliance on imported diagnostic tools will gradually decrease, enhancing self-sufficiency and ensuring a steady supply of essential test kits.
Dr. Daniel Kyabayinze, Director of Public Health at the Ministry of Health, officiated the handover ceremony and emphasized the reliability and quality of the newly produced kits.
“These RDT kits have undergone rigorous assessment and have been approved by all relevant regulatory bodies. We are confident that they meet the highest standards, ensuring accuracy and effectiveness in disease detection,” Dr. Kyabayinze stated.
Uganda has long depended on imported diagnostic kits, which cost the country an estimated $100 million annually.
With local production now in place, these funds can be redirected to other critical areas of the health sector, including infrastructure development, medical research, and enhanced patient care. Additionally, the local manufacturing of RDT kits is expected to create job opportunities, boost technological innovation, and contribute to the country’s economic growth.
The affordability of the locally-produced kits will also significantly enhance accessibility, especially in rural areas where healthcare resources are often scarce. Timely and accurate diagnosis is crucial in combating diseases such as malaria, which remains one of Uganda’s leading causes of morbidity and mortality.
Similarly, early detection of HIV and sickle cell disease can lead to better treatment outcomes and improved quality of life for affected individuals.
With the successful launch of the first batch of RDT kits, plans are already in motion to scale up production and expand to other types of diagnostic tests. The government, in collaboration with private sector stakeholders, aims to establish Uganda as a leading hub for medical diagnostics in the region.
“This is just the beginning,” Dr. Kyabayinze noted.
“We envision a future where Uganda not only meets its own diagnostic needs but also supplies neighboring countries, positioning itself as a key player in the global healthcare supply chain.”
The commissioning of the MHS plant aligns with Uganda’s broader goal of strengthening its healthcare sector through local innovation and manufacturing.
As the country takes bold steps towards self-reliance in medical diagnostics, the impact will be felt not just in cost savings but in improved health outcomes for millions of Ugandans.
With continued support from the government, regulatory bodies, and international health organizations, the local production of RDT kits stands as a testament to Uganda’s commitment to advancing public health through homegrown solutions.
Join the Daily West Nile WhatsApp group now to never miss an update from us.Download Host Media Now from the Play Store to watch HostTV, listen to Host Radio Live, and stay informed—all in one convenient app!
Source. Ind
